Sharps Technology signs $50M+ SoloGard syringe deal; sets $5M 2025 revenue target

Sharps Technology Inc.

Entered $50M+ 5-year supply agreement for 500M SoloGard 10mL syringes with U.S. pharma company; deliveries begin Q1 2025.
Signed sales agreement with European medical supply company for SecureGard 1mL/3mL inventory; first revenue in early December 2024.
Revenue guidance: ~$400K Dec 2024, >$5M in 2025, $15M in 2026, $20M in 2027 from Hungary facility.
Regained compliance with NASDAQ listing rules as of November 13, 2024.
Hungary expansion targets SecureGard capacity >100M units and SoloGard >125M units annually.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.